Theravance Biopharma (NASDAQ:TBPH) Raised to “Strong-Buy” at Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Sunday.

A number of other analysts also recently issued reports on the stock. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. BTIG Research reiterated a “buy” rating and issued a $21.00 price target on shares of Theravance Biopharma in a research note on Friday, March 20th. HC Wainwright boosted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, TD Cowen increased their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Theravance Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $21.33.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $15.08 on Friday. The company’s fifty day moving average price is $17.49 and its two-hundred day moving average price is $16.91. Theravance Biopharma has a 52-week low of $7.90 and a 52-week high of $21.03. The firm has a market capitalization of $776.47 million, a PE ratio of 7.43 and a beta of 0.17.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Quarry LP bought a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.